Stay updated on Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.

Latest updates to the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
- Check34 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check63 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check77 days agoChange DetectedThe web page has been updated to version 2.15.0 from version 2.14.4, indicating a revision in the content. The phrase 'Here’s how you know' has been modified to 'Here's how you know', which does not significantly alter the core content.SummaryDifference1.0%
- Check84 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
Stay in the know with updates to Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.